North American Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & (Deuterium, C-13) - Forecast to 2017

北米における核医学/放射性医薬品&安定同位体市場

◆タイトル:North American Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & (Deuterium, C-13) - Forecast to 2017
◆商品コード:PH 1868
◆調査・発行会社:MarketsandMarkets
◆発行日:2013年4月
◆ページ数:280
◆レポート形式:pdf / 英語
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆販売価格オプション(消費税別)
Single userUSD5,650 ⇒換算¥604,550見積依頼/購入/質問フォーム
Multi User(~5名まで)USD6,650 ⇒換算¥711,550見積依頼/購入/質問フォーム
Corporate licence(社内共有可)USD8,150 ⇒換算¥872,050見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarketsの日本における正規販売代理店です。

【レポートの概要】

本調査レポートでは、"北米における核医学/放射性医薬品&安定同位体市場"について調査・分析し、イントロダクション、エグゼクティブサマリー、市場概観、市場の成長要因、阻害要因、市場の機会と課題、市場環境分析、市場の動態、用途別分析、地域別分析、市場規模及び予測、競争状況、市場シェア分析、主要企業(ベンダー)分析等の情報をお届けいたします。

The North American radiopharmaceuticals market was valued at $1.9 billion in 2012 and is poised to reach $2.7 billion by 2017 at a CAGR of 7.2%.

A study conducted by Organization for Economic Co-operation and Development (OECD) estimates that Tc-99m diagnostic procedures are expected to increase by 15% to 20% in mature markets such as North America between 2010 and 2030. Radiopharmaceuticals in neurological applications such as Alzheimer’s disease, Parkinson’s disease, and dementia are also being preferred by practitioners besides conventional treatment. Further, upcoming radioisotopes such as Ra-223 (Alpharadin) and Ga-68 possess huge potential for clinical applications. The scheduled shutdown of the NRU reactor in 2016 in Canada is, however, a major threat for manufacturers.

The therapy market is predominantly driven by its oncologic applications. Since conventional treatment procedures of cancer, surgery and chemotherapy have significant side effects; radioisotopes are being preferred by medical practitioners due to minimum or no side effects. The radiopharmaceutical therapy market is expected to grow significantly with the launch of the much-desired Alpharadin (Ra-223) in the near future. This isotope has tremendous potential to take up market share of beta emitters and brachytherapy.

The U.S. is the dominant market for diagnostic radioisotopes with more than 80% share. The U.S. is the largest consumer market for radiopharmaceuticals in North America, while Canada is one of the largest producers of Tc-99m. Major players in the radiopharmaceuticals market are Cardinal Health, Inc. (U.S.), Lantheus Medical Imaging, Inc. (U.S.), Nordion, Inc. (Canada), and Triad Isotopes, Inc. (U.S.).

The stable isotopes market was led by two players – Cambridge Isotope Laboratories (CIL) and Sigma Aldrich – in 2012; they jointly contributed more than 90% to the North American revenue.

Scope of the Report

The radioisotope and stable isotope markets have been segmented according to the type of isotope, and applications. Both of these markets are broken down into segments and sub-segments, providing exhaustive value analysis for the years 2010, 2011, 2012, and forecast to 2017. Each market is comprehensively analyzed at a granular level by country (U.S. and Canada) to provide in-depth information on the country basis.

North American Radiopharmaceuticals Market

Diagnostic
SPECT
Tc-99m
Tl-201
Ga-67
I-123
Others
PET
F-18
Rb-82
Others
Therapy
Beta emitters
I-131
Sm-153
Re-186
Y-90
Lu-177
Others
Alpha emitters
Brachytherapy
Cs-131
I-125
Pd-103
Ir-192
Others
North American Enriched Stable Isotopes Market

Deuterium
Oxygen-18
Carbon-13
Nitrogen-15
Others
North American Radiopharmaceutical and Stable Isotope Markets, By Country

U.S.
Canada

【レポートの目次】

Table Of Contents

1 Introduction (Page No.- 26)
1.1 Key Take-Aways
1.2 Report Description
1.3 Markets Covered
1.4 Stakeholders
1.5 Research Methodology
1.5.1 Market Size
1.5.2 Market Share
1.5.3 Key Data Points From Secondary Sources
1.5.4 Key Data Points From Primary Sources
1.5.5 Assumptions

2 Executive Summary (Page No.- 33)

3 Market Overview (Page No.- 37)
3.1 Definition Of Radiopharmaceuticals
3.2 Evolution
3.3 Market Segmentation
3.3.1 Radiopharmaceuticals
3.3.2 Stable Isotopes
3.4 Market Dynamics
3.4.1 Drivers
3.4.1.1 Increasing Incidence Of Cancer And Cardiac Ailments Boosts The Demand For Radiopharmaceuticals
3.4.1.2 Increasing Use Of Spect And Pet Scans Results In The Rise Of Radiopharmaceutical Usage
3.4.1.3 Rising Awareness Of Radiopharmaceuticals To Spur Growth
3.4.1.4 Ready Availability Of Radiopharmaceuticals From Cyclotrons To Goad The Growth
3.4.2 Restraints
3.4.2.1 Shorter Half-Life Of Radiopharmaceuticals To Restrict Usage
3.4.2.2 High Capital Demand To Limit The Buying Of Scanners
3.4.2.3 Stringent Regulatory Guidelines And Gmp To Negatively Impact Growth
3.4.2.4 Competition From Conventional Diagnostic Procedures
3.4.3 Opportunities
3.4.3.1 Ample Number Of Potential Radioisotopes In The Pipeline
3.4.3.2 Alpha Radioimmunotherapy-Based Targeted Cancer Treatment
3.4.3.3 Alternative Diagnostic Radiopharmaceuticals Solution
3.4.3.4 Cyclotron-Based Production
3.4.3.5 Neurological Application
3.4.4 Threat
3.4.4.1 Shutdown Of Nuclear Reactors Impacts The Production Of Radioisotopes
3.5 Winning Imperatives
3.5.1 Investment To Encourage New Radioisotopes And Novel Applications
3.5.2 Shift Towards Leu Based Mo-99 Production
3.6 Burning Issues
3.6.1 High Cost Of Pet Cameras
3.6.2 Shortage In Supply Of Technetium-99m
3.7 Supply And Demand Analysis Of Technetium-99m
3.8 Regulatory Affairs
3.8.1 U.S.
3.8.1.1 Fda Approval Process
3.8.1.2 Transportation
3.8.1.3 Reimbursement Scenario
3.8.2 Canada
3.8.2.1 Nuclear Safety And Control Act
3.8.2.2 Transportation
3.8.2.3 Licensing
3.9 Market Share Analysis
3.9.1 Radiopharmaceuticals Market
3.9.2 Enriched Stable Isotopes Market

4 North American Radiopharmaceuticals Market, By Isotope (Page No.- 61)
4.1 Introduction
4.2 Diagnostic Isotopes
4.2.1 Opportunity Matrix
4.2.2 Single-Photon Emission Computed Tomography (Spect) Radiopharmaceuticals
4.2.2.1 Technetium-99m (TC-99M)
4.2.2.1.1 Tc-99m To Decide Growth Trend Of Spect Radioisotopes
4.2.2.1.2 Factors Affecting Technetium-99m Market
4.2.2.1.2.1 Technetium Can Combine With 31 Different Carrier Molecules
4.2.2.1.2.2 Lack Of Availability Of Technetium
4.2.2.2 Thallium-201 (TL-201)
4.2.2.2.1 Tl-201 Is A Potential Substitute For Tc-99m
4.2.2.3 Gallium-67 (GA-67)
4.2.2.3.1 Fluorine-18 Might Seize GA-67 Market Share In The Near Future
4.2.2.4 Iodine (I-123)
4.2.2.5 Others
4.2.3 Positron Emission Tomography (PET) Radiopharmaceuticals
4.2.3.1 Fluorine-18
4.2.3.1.1 FDG
4.2.3.1.2 Florbetapir
4.2.3.1.3 Factors Affecting Fluorine-18 Market
4.2.3.1.3.1 Increasing Availability Of Pet Machines
4.2.3.1.3.2 Rise In Pet Procedures Increases Demand For FDG
4.2.3.1.3.3 High Generation Costs Of FDG
4.2.3.1.3.4 Need For Speedy & Efficient Transportation
4.2.3.2 Rubidium-82 (RB-82)
4.2.3.2.1 Bracco Re-Launched Cardiogen-82 In FEB-12
4.2.3.3 Others
4.2.3.3.1 GA-68 Deemed As A Potential Pet Radioisotope
4.3 Therapeutic Isotopes
4.3.1 Opportunity Matrix
4.3.2 Beta Emitters
4.3.2.1 Iodine-131 (I-131)
4.3.2.2 Yttrium-90 (Y-90)
4.3.2.2.1 Y-90 Market Influenced By Popularity Of Nordion’s Therasphere
4.3.2.3 Samarium-153 (SM-153)
4.3.2.4 Rhenium-186 (RE-186)
4.3.2.5 Lutetium-177 (LU-177)
4.3.2.5.1 Lu-177 Is A Potential Treatment Option For Neuroendocrine Cancer
4.3.2.6 Others
4.3.2.6.1 Re-188 And P-33 Are Notable Promising Isotope
4.3.3 Alpha Emitters
4.3.3.1 Radium-223 (RA-223) & Alpharadin
4.3.3.1.1 Successful Completion Of Phase Iii Trials In Men With Bone Metastases From Crpc
4.3.3.1.2 First In-Class Alpha Pharmaceutical
4.3.3.1.3 Alpharadin Is Advantageous Over Taxotere, Beta-Therapy And Brachytherapy
4.3.3.1.4 Success Of Alpharadin
4.3.3.1.5 Porter’s Five Forces Analysis
4.3.3.1.6 Swot Analysis
4.3.3.2 Actinium-225 (AC-225)
4.3.3.3 Lead-212 (PB-212)/Bismuth-212 (BI-212)
4.3.3.4 Astatine-211 (AT-211)
4.3.3.5 Radium-224 (RA-224)
4.3.3.6 Thorium-227 (TH-227)
4.3.4 Brachytherapy
4.3.4.1 U.S. To Show Slow Growth Due To Reimbursement Issues
4.3.4.2 Cesium-131
4.3.4.3 Iodine-125
4.3.4.4 Palladium-103
4.3.4.5 Iridium-192
4.3.4.6 Others

5 North American Radiopharmaceuticals Market, By Application/Indications (Page No.- 113)
5.1 Introduction
5.2 Diagnostic Application
5.2.1 Spect
5.2.1.1 Cardiology
5.2.1.2 Lymphoma
5.2.1.3 Thyroid
5.2.1.4 Neurology
5.2.1.4.1 Alzheimer’s, Dementia, And Parkinson’s Disease Drive Growth Of The Neurology Spect Market
5.2.1.5 Others
5.2.2 Pet
5.2.2.1 Oncology
5.2.2.1.1 Fdg F-18 Has Become A Gold Standard For Oncology Diagnosis Using Pet Scan
5.2.2.2 Cardiology
5.2.2.3 Neurology
5.2.2.3.1 Florbetapir F-18 & Fluorodopa (F-18 Dopa) Are Potential Substitutes Of FDG F-18
5.2.2.4 Others
5.3 Therapeutic Application
5.3.1 Thyroid
5.3.2 Bone Metastasis
5.3.3 Lymphoma
5.3.3.1 Novel Clinical Studies Goading Lymphoma Therapy Market
5.3.4 Endocrine Tumors
5.3.5 Others

6 North American Enriched Stable Isotopes Market (Page No.- 136)
6.1 Introduction
6.2 Market Overview
6.3 Market Dynamics
6.3.1 Drivers
6.3.1.1 Stable Isotopes Are Natural In Origin & Hence Safe
6.3.1.2 Proteomics & System Biology, Major Factors To Boost The Growth Of Stables
6.3.1.3 Medical Applications Propel Stable Isotopes Market Growth
6.3.2 Restraints
6.3.2.1 Harmful Effects Of High Doses Of Stable Isotopes Affect Market Growth
6.3.2.2 High Cost Of Stables Isotope
6.4 Enriched Stables Market, By Isotope
6.4.1 Deuterium & O-18 Are Promising Isotopes
6.4.2 Carbon-13
6.4.3 Deuterium
6.4.4 Oxygen-18
6.4.5 Nitrogen-15
6.4.6 Other Stable Isotopes
6.5 Enriched Stables Market, By Application
6.5.1 Diagnostic & Therapeutic
6.5.2 Research
6.5.3 Pharmaceutical
6.5.4 Industrial Sector

7 Geographic Analysis (Page No.- 154)
7.1 Introduction
7.2 U.S.
7.2.1 Diagnostic Radiopharmaceuticals Market
7.2.2 Therapeutic Radiopharmaceuticals Market
7.2.3 Stable Isotope Market
7.3 Canada
7.3.1 Diagnostic Radiopharmaceuticals Market
7.3.2 Therapeutic Radiopharmaceuticals Market
7.3.3 Stable Isotope Market

8 Competitive Landscape (Page No.- 183)
8.1 Introduction
8.2 Mergers & Acquisitions
8.3 Agreements, Partnerships, Collaborations & Joint Ventures 185
8.4 Products Launch
8.5 Expansions
8.6 Other Developments
8.7 Approvals

9 Company Profiles (Overview, Financials, Products & Services, Strategy, & Developments)* (Page No.- 195)
9.1 Bracco Imaging S.P.A.
9.2 Cambridge Isotope Laboratories, Inc.
9.3 Cardinal Health, Inc.
9.4 Covidien, Plc
9.5 Eczacibasi-Monrol
9.6 Fujifilm Holdings Corporation
9.7 Ge Healthcare (Subsidiary Of General Electric Company)
9.8 Iba Group
9.9 Isotec, Inc. (Sigma-Aldrich)
9.10 Lantheus Medical Imaging, Inc.
9.11 Nordion, Inc.
9.12 Ntp Radioisotopes (Pty), Ltd.
9.13 Petnet Solutions, Inc. (A Subsidiary Of Siemens Medical Solutions Usa, Inc.)
9.14 Taiyo Nippon Sanso Corporation
9.15 Triad Isotopes, Inc.
9.16 Urenco Limited
9.17 Rotem Industries, Ltd., Inc.
9.18 Australian Nuclear Association And Technology Organization (ANSTO)
9.19 Board Of Radiation And Isotope Technology (BRIT)
9.20 Institute Of Atomic Energy Polatom Radioisotope Centre
9.21 Institute Of Isotopes Co., Ltd.
9.22 Institute Of Radioelement (IRE)

*Details On Financials, Product & Services, Strategy, & Developments Might Not Be Captured In Case Of Unlisted Companies.

List Of Tables (120 Tables)

Table 1 North America: Diagnostic Radiopharmaceuticals Market,By Technology, 2010 - 2017 ($Million)
Table 2 North America: Radioipharmaceuticals Market, By Country, 2010 - 2017 ($Million)
Table 3 North America: Diagnostic Radiopharmaceuticals Market,By Technology, 2010 - 2017 ($Million)
Table 4 North America: Spect Radiopharmaceuticals Market,By Isotope, 2010 - 2017 ($Million)
Table 5 North America: Spect Radiopharmaceuticals Market,By Country, 2010 - 2017 ($Million)
Table 6 Indications Diagnosed By Tc-99m
Table 7 North America: TC-99M Market, By Country, 2010- 2017 ($Million)
Table 8 North America: Tl-201 Market, By Country, 2010 - 2017 ($Million)
Table 9 North America: GA-67 Market, By Country, 2010 - 2017 ($Million)
Table 10 North America: I-123 Market, By Country, 2010 - 2017 ($Million)
Table 11 North America: Other Radiopharmaceuticals Market,By Country, 2010 - 2017 ($Million)
Table 12 North America: Pet Radiopharmaceuticals Market, By Country, 2010 - 2017 ($Million)
Table 13 North America: Pet Radiopharmaceuticals Market, By Isotope, 2010 - 2017 ($Million)
Table 14 North America: F-18 Market, By Country, 2010 - 2017 ($Million)
Table 15 North America: RB-82 Market, By Country, 2010 - 2017 ($Million)
Table 16 North America: Other Pet Radiopharmaceuticals Market, By Country, 2010 - 2017 ($Million)
Table 17 North America: Therapeutic Radiopharmaceuticals Market, By Technology 2010 - 2017 ($Million)
Table 18 North America: Beta Emitters Market, By Isotope, 2010 - 2017 ($Million)
Table 19 North America: Beta Emitter Radiopharmaceuticals Market, By Country, 2010 - 2017 ($Million)
Table 20 North America: I-131 Market, By Country, 2010 - 2017 ($Million)
Table 21 North America: Y-90 Market, By Country, 2010 - 2017 ($Million)
Table 22 North America: SM-153 Market, By Country, 2010 - 2017 ($Million)
Table 23 North America: RE-186 Market, By Country, 2010 - 2017 ($Million)
Table 24 North America: LU-177 Market, By Country, 2010 - 2017 ($Million)
Table 25 North America: Other Beta Emitters Market, By Country, 2010 - 2017 ($Million)
Table 26 Alpha Emitters Vs Beta Emitters
Table 27 Radioisotope Characteristics & Dose Delivery Over Time
Table 28 North America: Brachytherapy Market, By Isotope, 2010 - 2017 ($Million)
Table 29 North America: Brachytherapy Market, By Country, 2010 - 2017 ($Million)
Table 30 North America: CS-131 Market, By Country, 2010 - 2017 ($Million)
Table 31 North America: I-125 Market, By Country, 2010 - 2017 ($Million)
Table 32 North America: PD-103 Market, By Country, 2010 - 2017 ($Million)
Table 33 North America: IR-192 Market, By Country, 2010 - 2017 ($Million)
Table 34 North America: Other Brachytherapy Market, By Country, 2010 - 2017 ($Million)
Table 35 North America: Spect Application Market, 2010 - 2017 ($Million)
Table 36 North America: Cardiology Spect Market, By Country, 2010 - 2017 ($Million)
Table 37 North America: Lymphoma Spect Market, By Country, 2010 - 2017 ($Million)
Table 38 North America: Thyroid Spect Market, By Country, 2010 - 2017 ($Million)
Table 39 North America: Neurology Spect Market, By Country, 2010 - 2017 ($Million)
Table 40 North America: Other Spect Applications Market, By Country, 2010 - 2017 ($Million)
Table 41 North America: Pet Market, By Application, 2010 - 2017 ($Million)
Table 42 North America: Oncology Pet Market, By Country, 2010 - 2017 ($Million)
Table 43 North America: Cardiology Pet Market, By Country, 2010 - 2017 ($Million)
Table 44 North America: Neurology Pet Market, By Country, 2010 - 2017 ($Million)
Table 45 North America: Other Pet Applications Market, By Country, 2010 - 2017 ($Million)
Table 46 North America: Therapeutic Application Market, 2010 - 2017 ($Million)
Table 47 North America: Radiopharmaceuticals Therapeutic Application Market, By Country, 2010 - 2017 ($Million)
Table 48 North America: Radiopharmaceuticals Thyroid Application Market, By Country, 2010 - 2017 ($Million)
Table 49 North America: Radiopharmaceuticals Bone Metastasis Application Market, By Country, 2010 - 2017 ($Million)
Table 50 North America: Radiopharmaceuticals Lymphoma Application Market, By Country, 2010 - 2017 ($Million)
Table 51 North America: Radiopharmaceuticals Endocrine Application Market, By Country, 2010 - 2017 ($Million)
Table 52 North America: Radiopharmaceuticals Other Application Market, By Country, 2010 - 2017 ($Million)
Table 53 North America: Stable Isotope Market, 2010 - 2017 ($Million)
Table 54 North America: Stable Isotope Market, By Country, 2010 - 2017 ($Million)
Table 55 North America: Carbon Stable Isotope Market, By Country, 2010 - 2017 ($Million)
Table 56 North America: Deuterium Stable Isotope Market, By Country, 2010 - 2017 ($Million)
Table 57 North America: Oxygen Stable Isotope Market, By Country, 2010 - 2017 ($Million)
Table 58 North America: Nitrogen Stable Isotope Market, By Country, 2010 - 2017 ($Million)
Table 59 North America: Other Stable Isotope Market, By Country, 2010 - 2017 ($Million)
Table 60 North America: Enriched Stable Isotope Market, For Application, 2010 - 2017 ($Million)
Table 61 North America: Stable Isotopes Market For Diagnostic & Therapy Applications, By Country, 2010 - 2017 ($Million)
Table 62 North America: Stable Isotopes Market For Research Applications, By Country, 2010 - 2017 ($Million)
Table 63 North America: Stable Isotopes Market For Pharmaceutical Applications, By Country, 2010 - 2017 ($Million)
Table 64 North America: Stable Isotopes Market For Industrial Applications, By Country, 2010 - 2017 ($Million)
Table 65 North America: Diagnostic Radiopharmaceuticals Market, By Technology, 2010 - 2017 ($Million)
Table 66 North America: Spect Radiopharmaceuticals Market, By Country, 2010 - 2017 ($Million)
Table 67 North America: Spect Radiopharmaceuticals Market, By Isotope, 2010 - 2017 ($Million)
Table 68 North America: Pet Radiopharmaceuticals Market, By Country, 2010 - 2017 ($Million)
Table 69 North America: Pet Radiopharmaceuticals Market, By Isotope, 2010 - 2017 ($Million)
Table 70 North America: Therapeutic Radiopharmaceuticals Market, 2010 - 2017 ($Million)
Table 71 North America: Beta Emitters Market, By Country, 2010 - 2017 ($Million)
Table 72 North America: Beta Emitters Market, By Isotope, 2010 - 2017 ($Million)
Table 73 North America: Brachytherapy Market, By Country, 2010 - 2017 ($Million)
Table 74 North America: Brachytherapy Market, By Isotope, 2010 - 2017 ($Million)
Table 75 North America: Stable Isotopes Market, By Country, 2010 - 2017 ($Million)
Table 76 North America: Stable Isotopes Market, 2010 - 2017 ($Million)
Table 77 North America: Stable Isotopes Market, By Application, 2010 - 2017 ($Million)
Table 78 U.S.: Diagnostic Radiopharmaceuticals Market, By Technology, 2010 - 2017 ($Million)
Table 79 U.S.: Spect Radiopharmaceuticals Market, By Isotope, 2010 - 2017 ($Million)
Table 80 U.S.: Pet Radiopharmaceuticals Market, By Isotope, 2010 - 2017 ($Million)
Table 81 U.S.: Therapeutic Radiopharmaceuticals Market, 2010 - 2017 ($Million)
Table 82 U.S.: Brachytherapy Market, By Isotope, 2010 - 2017 ($Million)
Table 83 U.S.: Beta Emitter Market, By Isotope, 2010 - 2017 ($Million)
Table 84 U.S.: Stable Isotopes Market, 2010 - 2017 ($Million)
Table 85 Canada: Diagnostic Radiopharmaceuticals Market, By Technology, 2010 - 2017 ($Million)
Table 86 Canada: Spect Radiopharmaceuticals Market, By Isotope, 2010 - 2017 ($Million)
Table 87 Canada: Pet Radiopharmaceuticals Market, By Isotope, 2010 - 2017 ($Million)
Table 88 Canada: Therapeutic Radiopharmaceuticals Market, 2010 - 2017 ($Million)
Table 89 Canada: Brachytherapy Market, By Isotope, 2010 - 2017 ($Million)
Table 90 Canada: Beta Emitter Market, By Isotope, 2010 - 2017 ($Million)
Table 91 Canada: Stable Isotopes Market, 2010 - 2017 ($Million)
Table 92 Mergers & Acquisitions, 2010 - 2012
Table 93 Agreements, Partnerships, Collaborations & Joint Ventures, 2010 - 2013
Table 94 Products Launch, 2010 - 2013
Table 95 Expansion, 2010 - 2012
Table 96 Other Developments, 2010 - 2012
Table 97 Approvals, 2010 - 2012
Table 98 Cambridge Isotope Laboratories Inc.: Total Revenue, By Segment, 2010 - 2012 ($Million)
Table 99 Cambridge Isotope Laboratories Inc.: Total Revenue, By Geography, 2010 - 2012 ($Million)
Table 100 Cardinal Health, Inc.: Total Revenue, By Segment, 2010 - 2012 ($Million)
Table 101 Cardinal Health, Inc.: Total Revenue, By Geography, 2010 - 2012 ($Million)
Table 102 Covidien, Plc: Total Revenue And R&D Expenditure, 2010 - 2012 ($Million)
Table 103 Covidien, Plc: Total Revenue, By Segment, 2010 - 2012 ($Million)
Table 104 Covidien, Plc: Total Revenue, By Geography, 2010 - 2012 ($Million)
Table 105 Fujifilm Holdings Corp: Total Revenue, By Segment, 2010 - 2012 ($Million)
Table 106 Fujifilm Holdings Corp: Total Revenue, By Geography, 2010 - 2012 ($Million)
Table 107 General Electric Company: Total Revenue, By Segment, 2009 - 2011 ($Billion)
Table 108 General Electric Company: Total Revenue, By Geography, 2009 - 2011 ($Billion)
Table 109 IBA Group: Market Revenue, By Segment, 2009 - 2011 ($Million)
Table 110 IBA Group: Total Revenue, By Geography, 2009 - 2011 ($Million)
Table 111 Isotec Inc.: Total Revenue, By Segment, 2009 - 2011 ($Million)
Table 112 Isotec Inc.: Total Revenue, By Geography, 2009 - 2011 ($Million)
Table 113 Lantheus: Total Revenue, By Segment, 2009 - 2011 ($Million)
Table 114 Lantheus: Total Revenue, By Geography, 2009 - 2011 ($Million)
Table 115 Nordion, Inc.: Total Revenue, By Segment, 2010 - 2012 ($Million)
Table 116 Nordion, Inc.: Total Revenue, By Geography, 2010 - 2017
Table 117 Siemens AG: Total Revenue And R&D Expenses, 2010 - 2012 ($Million)
Table 118 Siemens AG: Total Revenue, By Segment, 2010 - 2012 ($Million)
Table 119 Siemens AG: Total Revenue, By Geography, 2010 - 2012 ($Million)
Table 120 Taiyo Nippon Sanso, Corp.: Total Revenue, By Geography, 2010 - 2012 ($Million)


List Of Figures (29 Figures)

Figure 1 North American Radiopharmaceuticals Market, By Segment, 2010 - 2017
Figure 2 North America Stable Isotopes Market, $Million (2012 - 2017)
Figure 3 Evolution Of Radiopharmaceuticals
Figure 4 Radiopharmaceuticals Market Segmentation
Figure 5 Enriched Stable Isotopes Market Segmentation
Figure 6 Market Dynamics
Figure 7 Supply Chain Of Mo-99/TC-99M Between U.S. And Canada
Figure 8 North America: Radiopharmaceuticals Market Share Analysis, By Key Players, 2012
Figure 9 North America Enriched Stable Isotope Market: Market Share Analysis, By Key Players, 2012
Figure 10 Opportunity Matrix: North American Diagnostic Radiopharmaceuticals Market (2012)
Figure 11 Spect Radiopharmaceuticals Market Share (2012)
Figure 12 Pet Radiopharmaceuticals Market Share (2012)
Figure 13 Opportunity Matrix: North American Therapeutic Radiopharmaceuticals Market (2012)
Figure 14 RA-223 Decay Chain
Figure 15 Porter’s Five Forces Analysis For Alpharadin
Figure 16 Swot Analysis Of Alpharadin
Figure 17 North America: Diagnostic Radiopharmaceuticals Market, By Technology & Indication (2012 - 2017)
Figure 18 Key Growth Strategies, 2010 - 2013
Figure 19 Cambridge Isotope Laboratories Inc.: Total Revenue And R&D Expenses, 2010 - 2012 ($Billion)
Figure 20 Cardinal Health, Inc.: Total Revenue, 2010 - 2012 ($Billion)
Figure 21 Covidien, Plc: Radiopharmaceuticals Revenue, 2010 - 2012 ($Billion)
Figure 22 Fujifilm Holdings Corp: Total Revenue And R&D Expenditure, 2010 - 2012 ($Billion)
Figure 23 General Electric Company: Total Revenue And R&D Expenses, 2009 - 2011 ($Billion)
Figure 24 IBA Group: Total Market Revenue, 2009 - 2011 ($Million)
Figure 25 Isotec Inc.: Total Revenue And R&D Expenses, 2009 - 2011 ($Billion)
Figure 26 Lantheus: Total Revenue And R&D Expenses, L2009 - 2011 ($Million)
Figure 27 Nordion, Inc.: Total Market Revenue, 2010 - 2012 ($Billion)
Figure 28 Taiyo Nippon Sanso, Corp.: Total Revenue And R&D Expenditure, 2010 - 2012 ($Billion)
Figure 29 Urenco Limited: Total Market Revenue, 2009 - 2011, ($Billion)

★調査レポート[北米における核医学/放射性医薬品&安定同位体市場] ( North American Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & (Deuterium, C-13) - Forecast to 2017 / PH 1868) 販売に関する免責事項
[北米における核医学/放射性医薬品&安定同位体市場] ( North American Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & (Deuterium, C-13) - Forecast to 2017 / PH 1868) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆